Menora Mivtachim Holdings LTD. acquired a new stake in Pluristem Therapeutics Inc. (NASDAQ:PSTI) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,000,000 shares of the biotechnology company’s stock, valued at approximately $1,230,000. Menora Mivtachim Holdings LTD. owned approximately 1.04% of Pluristem Therapeutics at the end of the most recent reporting period.
Separately, Renaissance Technologies LLC raised its position in shares of Pluristem Therapeutics by 8.6% in the fourth quarter. Renaissance Technologies LLC now owns 1,424,800 shares of the biotechnology company’s stock worth $2,037,000 after buying an additional 113,300 shares during the period. 3.05% of the stock is currently owned by institutional investors and hedge funds.
Shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI) traded up 3.17% during trading on Friday, hitting $1.30. 103,581 shares of the stock were exchanged. The stock’s 50 day moving average price is $1.40 and its 200-day moving average price is $1.36. Pluristem Therapeutics Inc. has a one year low of $1.04 and a one year high of $1.85. The company’s market cap is $124.88 million.
WARNING: “Menora Mivtachim Holdings LTD. Acquires Shares of 1,000,000 Pluristem Therapeutics Inc. (PSTI)” was originally published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://transcriptdaily.com/2017/05/20/menora-mivtachim-holdings-ltd-acquires-shares-of-1000000-pluristem-therapeutics-inc-psti.html.
A number of brokerages have recently commented on PSTI. HC Wainwright set a $4.00 target price on shares of Pluristem Therapeutics and gave the stock a “buy” rating in a research report on Saturday, February 11th. Zacks Investment Research raised shares of Pluristem Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a research report on Wednesday, February 15th. Finally, Maxim Group reaffirmed a “hold” rating on shares of Pluristem Therapeutics in a research report on Thursday, May 4th.
About Pluristem Therapeutics
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.